InChI
1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
SMILES string
CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C
InChI key
UVTNFZQICZKOEM-UHFFFAOYSA-N
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
format
neat
storage temp.
2-8°C
Gene Information
正在寻找类似产品? 访问 产品对比指南
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Biochem/physiol Actions
IA 类抗心律失常药；钠通道阻断剂
法规信息
新产品
此项目有
Procainamide and disopyramide.
C Ribeiro et al.
European heart journal, 8 Suppl A, 11-19 (1987-03-01)
R N Brogden et al.
Drugs, 34(2), 151-187 (1987-08-01)
Disopyramide is a widely used class IA antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide. Over the past 10 years disopyramide has demonstrated its efficacy in ventricular and atrial arrhythmias. In therapeutic trials
S Y Kim et al.
Drug safety, 5(6), 393-420 (1990-11-01)
Quinidine, procainamide and disopyramide are antiarrhythmic drugs in the class 1A category. These drugs have a low toxic to therapeutic ratio, and their use is associated with a number of serious adverse effects during long term therapy and life-threatening sequelae
Annerie M E Moers et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14(3), 426-430 (2011-09-22)
Patients undergo ablation for focal atrial fibrillation (AF) as a result of failure of anti-arrhythmic drugs. Our basic studies have implicated cholinergic and adrenergic neurotransmitter release as the underlying mechanism for focal AF. Therefore, we tested the efficacy of a
Koji Nishi et al.
The Journal of biological chemistry, 286(16), 14427-14434 (2011-02-26)
Human α(1)-acid glycoprotein (hAGP) in serum functions as a carrier of basic drugs. In most individuals, hAGP exists as a mixture of two genetic variants, the F1*S and A variants, which bind drugs with different selectivities. We prepared a mutant
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持